Iconic Labs PLC
("Iconic" or the "Company")
Conversion of Notes and Allotment of Shares
Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion Notice from the European High Growth Opportunities Securitization Fund and has allotted 8,168 ordinary shares of £0.00001 ("Ordinary Shares") to AMBA Company Secretarial Services Limited ("AMBA).
The Conversion Notice was dated 16 August 2023 and provides for 20 Convertible Notes to be converted into 689,655,172 Ordinary Shares of £0.00001 in the Company at a conversion price of £0.000029 at the aggregate principal amount of £20,000.
In addition, 8,168 Ordinary Shares were allotted to AMBA . The allotment was necessary to ensure that the issued ordinary share capital of the Company can be divided by 10,000 in anticipation of the AGM to be held at 3pm on 25 August 2023. Resolution 9 of the AGM provides for the issued ordinary share capital of the Company to be consolidated and divided into ordinary shares of £0.1 each, such shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing ordinary shares of £0.00001 each in the capital of the Company as set out in the Company's Articles of Association for the time being.
Application is being made for 689,663,340 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 23 August 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.
Following the issue of these shares, the Company's issued ordinary share capital shall consist of 46,996,580,000 Ordinary Shares. The figure of 46,996,580,000 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
For any further information or enquiries please contact:
ir@iconiclabs.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
